May 06, 2022

Anthos goes pivotal as Novartis and Pfizer look on

April 05, 2022

ACC 2022 – Astra’s cholesterol lowerer surprise comes just a little late

April 04, 2022

ACC 2022 – Silence takes on Novartis and Amgen

April 04, 2022

ACC 2022 – full vupanorsen data shed light on Pfizer’s split

March 31, 2022

Amylyx’s chances rest on a knife edge

March 30, 2022

Biotech catalysts on the horizon

The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.

March 29, 2022

Amylyx faces an uphill battle

Briefing documents show why the FDA should await more data on the ALS project, but will it bow to patient pressure?

March 28, 2022

Biogen and Ionis stumble again

January 18, 2022

Roche and Ionis bring tominersen back from the dead